KSI-301

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Non-proliferative Diabetic Retinopathy

Conditions

Non-proliferative Diabetic Retinopathy

Trial Timeline

Sep 7, 2021 → Aug 31, 2023

NCT ID

NCT05066230

About KSI-301

KSI-301 is a phase 3 stage product being developed by Kodiak Sciences for Non-proliferative Diabetic Retinopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT05066230. Target conditions include Non-proliferative Diabetic Retinopathy.

What happened to similar drugs?

0 of 1 similar drugs in Non-proliferative Diabetic Retinopathy were approved

Approved (0) Terminated (0) Active (1)

🔄Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 + Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24Ocular TherapeutixPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05066230	Phase 3	Terminated	Sep 7, 2021	Aug 31, 2023	Non-proliferative Diabetic Retinopathy
NCT03790852	Phase 1	Terminated	Dec 26, 2018	Jun 9, 2022	Wet Age-related Macular Degeneration

Competing Products

2 competing products in Non-proliferative Diabetic Retinopathy

See all competitors

Product	Company	Stage	Hype Score
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 + Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24	Ocular Therapeutix	Phase 3	41
OTX-TKI + Sham	Ocular Therapeutix	Phase 1	19